Endocuff Enhanced Colonoscopy: Does it Improve Polyp Detection and Make Rectal Retroflexion Unnecessary
Launched by HOPITAL MONTFORT · Nov 8, 2022
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Every day, 73 Canadians are diagnosed with colorectal cancer. This cancer is the third most diagnosed type of cancer in Canada while being the second and third most deadly cancer for men and women respectively. In addition, it accounts for 12% of all cancer diagnoses and cancer deaths for both sexes in 2020. Fortunately, colorectal cancer incidence and mortality rates have been steadily declining in the recent years. This can be attributed to the development of new screening methods and devices assisting in a more reliable identification of polyps as well as removal during colonoscopy. This...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient undergoing a colonoscopy during the study period
- • Procedure being performed by a gastroenterologist (i.e., surgeons are excluded)
- Exclusion Criteria:
- • Inflammatory Bowel Disease
- • Hereditary Mixed Polyposis Syndrome
- • Diverticulitis
- • Colonic stricture
- • Toxic Megacolon
- • Previous Colon surgery, excluding appendectomy
- • Radiation therapy to abdomen or pelvis
- • Pregnancy/Lactation
- • Anticoagulant use
- • Suffered stroke or ischemia in previous 3 months
- • Being deemed too risky by investigator
- • FIT positive
- • Poor preparation
About Hopital Montfort
Hôpital Montfort is a leading healthcare institution dedicated to providing high-quality medical services and advancing clinical research. Located in Ottawa, Canada, the hospital is recognized for its commitment to patient-centered care and innovation in health sciences. As a prominent sponsor of clinical trials, Hôpital Montfort collaborates with a multidisciplinary team of healthcare professionals to foster groundbreaking research aimed at improving treatment outcomes across various medical fields. The institution prioritizes ethical standards and patient safety, ensuring that all trials contribute valuable insights to the medical community while enhancing the overall health and well-being of the populations it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Patients applied
Trial Officials
Philip Hassard, MD
Principal Investigator
Hopital Montfort
Christine-Nadia Compas, CRC
Study Director
Hopital Montfort
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials